| 
		Walmart, CVS to halt filling prescriptions for controlled substances by 
		Cerebral, Done
		 Send a link to a friend 
		
		 [May 26, 2022] 
		(Reuters) -Walmart Inc and CVS 
		Health Corp said on Wednesday they would stop filling prescriptions for 
		controlled substances issued by telehealth startups Cerebral Inc and 
		Done Health. 
 Cerebral and Done are known for treating patients with ADHD, prescribing 
		stimulants such as Adderall.
 
 Walmart confirmed the move to Reuters and said the decision was made 
		after an audit and compliance process.
 
 CVS said it would not accept prescriptions for controlled substances 
		issued by the startups effective May 26, as a result of a review it 
		conducted on the telehealth firms and after it was "unable to resolve 
		concerns we have with Cerebral and Done Health."
 
		
		 
		Cerebral had earlier this month decided to stop prescribing controlled 
		substances and taper existing prescriptions based on the impending 
		expiration of waivers, the company said in an emailed statement.
 The company was working to ensure that existing patients with controlled 
		substance prescriptions are able to receive their medications, while 
		working with the pharmacies to allow sufficient time to adjust to the 
		changes, Cerebral said.
 
		[to top of second column] | 
            
			 
            
			 CVS Health logo is seen displayed in this illustration taken, May 
			3, 2022. REUTERS/Dado Ruvic/Illustration 
            
			
			
			 The company said it plans to 
			continue to prescribe controlled substances to treat opioid use 
			disorder.
 Done Health did not respond to a request for comment.
 
 According to a Wall Street Journal earlier this month, Cerebral had 
			been issued a subpoena by federal prosecutors as part of an 
			investigation into possible violations of the Controlled Substances 
			Act.
 
 (Reporting by Ananya Mariam Rajesh, Juby Babu and Siddharth Cavale 
			in Bengaluru; editing by Uttaresh.V and Sriraj Kalluvila)
 
			[© 2022 Thomson Reuters. All rights 
				reserved.]  This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			 |